Neuraxpharm

We are thrilled to share the success of Neuraxpharm's partnership with Maudsley Learning and the KHP Psychosis Clinical Academic Group in organizing the one-day symposium: “Psychosis: Translating World-Class Research into Clinical Care.”   This impactful event brought together 219 healthcare professionals, both online and in-person, to explore the latest advancements in psychosis treatment. At Neuraxpharm, we remain deeply committed to medical education and advancing Central Nervous System care. Our collaboration with Maudsley Learning underscores our dedication to improving patient outcomes through cutting-edge research and clinical practice.   Together, we continue to strive towards enhancing the quality of care for patients worldwide.   #MedicalEducation #CNS #Psychosis #Neuraxpharm #HealthcareInnovation #PatientCare

A recent Patient Worthy article highlights that although Rare Disease Day has passed, 'the fight for rare disease awareness continues'.   The article shines a spotlight on the special information film by #Neuraxpharm and our partner, Minoryx Therapeutics, which provides insight into #cerebral adrenoleukodystrophy, the patient experience and the need for new treatments.   The film features world renowned expert Prof Fanny Mochel, the Director of the Reference Center for Leukodystrophies - La Pitié-Salpêtrière Hospital, Paris, and Karen Harrison, Support Services Manager of Alex The Leukodystrophy Charity (Alex TLC).   Find out more about #cALD in the article linked here: https://lnkd.in/dU3ETH2F   #CNS #cALD #cerebral adrenoleukodystrophy

Reinforcing Collaboration and Innovation at the STARS Event! We at Neuraxpharm are thrilled to share the success of our recent 𝗦𝗧𝗔𝗥𝗦 event - the 𝗦hare bes𝗧 pr𝗔ctices wo𝗥k𝗦hop! This unique gathering brought together brilliant minds from our commercial and medical teams across our European affiliates, all united by a common goal: to exchange ideas and recognize the best practices that can be replicated globally. The STARS event wasn't just a workshop; it was a celebration of collaboration, innovation, and our collective commitment to excellence. By sharing our experiences and insights, we are enhancing our ability to serve the healthcare professionals who rely on us, and ultimately, improving patient care around the world. A heartfelt thank you to everyone who participated and made this event a shining success. Your contributions are paving the way for a brighter, healthier future. Here's to the power of shared knowledge and teamwork! #Neuraxpharm #STARSWorkshop #InnovationInHealthcare #BestPractices #GlobalTeam #PatientCare #Collaboration

Neuraxpharm advocates for better transition period of services in epilepsy. As many as 1 in 3 young people have said that their experience of moving from child to adult epilepsy services had a negative impact on their mental health. The transition from paediatric to adult healthcare should be a gradual process to give time for adolescents with epilepsy to prepare and discuss their concerns and needs as they develop and reach adulthood. This testimonial video, developed by Neuraxpharm in partnership with Young Epilepsy, shows different experiences from young people with epilepsy when they move to university education and the healthcare service that they received. It seems that more supportive programmes are needed to better understand the disease, the changes that can occur as people grow up and some recommendations to improve quality of life. #Epilepsy #Neuraxpharm #YoungEpilepsy #patients #transitionperiod #growingwithepilepsy

The Neuraxpharm Team Switzerland was pleased to attend the Annual Meeting of Swiss Neurological Society in Basel last week, which featured insightful discussions about the ongoing diagnostic and therapeutic challenges and advances in #neurology from experts in the field.   The motto of the meeting was: 'Quo vadis neuroinflammation? From pathophysiologic advances to novel treatment strategies.' and attendees included neurologists, researchers and neurological nursing staff.   At Neuraxpharm, we are driven by the aim to deliver relevant improvements in the life and wellbeing of patients with neurological and psychiatric disorders. We work hand in hand with healthcare professionals and scientific communities across Europe.   Schweizerische Neurologische Gesellschaft (SNG-SSN)   #pharmaceuticals #pharma #CNS

Promising new data shared by our partner Minoryx Therapeutics. Click here to find out more.

Neuraxpharm has launched Unfiltered Executive, an initiative to showcase our Executive Committee members, both in their professional and personal capacities.    Today, we are delighted to share our first interview which is with Javier Mercadé, Executive Advisor to the CEO & Head of Growth Markets. With his unmistakable charisma, he shares his advice and vision after nearly 20 years at the company contributing to the organisational purpose and business objectives of Neuraxpharm.   We look forward to seeing his growth initiatives continue to unfold as he works alongside his motivated team, and, on a personal note, we urge him to hurry up and get that new dog!   #Neuraxpharm #CNS

Neuraxpharm and Minoryx Therapeutics announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended not to grant marketing authorization for leriglitazone as a treatment for cerebral adrenoleukodystrophy (#cALD) following completion of the re-examination procedure. Minoryx and Neuraxpharm had sought re-examination for conditional marketing approval for patients with (cALD), which is characterized by demyelinating brain lesions which can become rapidly progressive, leading to acute neurological decline and death in three to four years. The companies continue to believe that leriglitazone could be a lifesaving treatment for these patients in a devastating disease without available pharmacological treatment options and remain committed to bringing this new therapeutic option to patients. Find out more in the press release here: https://lnkd.in/dX5txwkU #CNS #pharmaceuticals #pharma

Neuraxpharm is attending the Bio International Convention in San Diego, the largest biotechnology industry event. This convention is an opportunity to foster valuable partnerships, explore strategic opportunities, and reinforce our positioning as #CNS leader in Europe. The conference provides a unique platform to engage with global industry leaders, brokers, established connections, emerging biotechs, tech partners and Venture Capital.   #Bio2024 #Biotech #Neuraxpharm #CNS

Today is World Multiple Sclerosis Day, which is an unpredictable disease of the Central Nervous System that affects millions of people around the world 🌍. 💪 Although it has no cure yet, there are treatments and therapies that can help reduce symptoms and improve patients’ quality of life. We join the Multiple Sclerosis community in giving voice to the importance of supporting the study and research of this disease, to find better treatment options and support those affected. Let’s fight together to make a difference! #WorldMSDay #MyMSDiagnosis #WorldMultipleSclerosisDay #MultipleSclerosis #EMawareness #MSawareness #TogetherWeAreStronger #Health #Neuraxpharm